IP Library Granted Patent US 8,017,161
Granted Patent B2
US 8,017,161 · App. 10/566,796 · Granted Sep 13, 2011

Bowman-Birk Inhibitor compositions for treatment of muscular atrophy and degenerative muscle disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,017,161
App. No.
10/566,796
Granted
Sep 13, 2011
Kind
B2
Abstract

Methods for use of a composition comprising Bowman-Birk Inhibitor (BBI) or a derivative thereof in the treatment and/or prevention of skeletal muscle atrophy, to improve of skeletal muscle function, and to alleviate symptoms and/or slow progression of degenerative skeletal muscle diseases or disorders are provided.

Claims (17)

1. A method for slowing progression of skeletal muscle atrophy in a subject comprising administering to the subject a composition comprising a therapeutically effective amount of Bowman-Birk Inhibitor.

2. The method of claim 1 wherein the composition is administered orally.

3. The method of claim 2 wherein the composition is administered as a dietary supplement.

4. The method of claim 1 wherein the Bowman-Birk Inhibitor is in a concentrated form.

5. A method for improving skeletal muscle function in a subject in need thereof comprising administering to the subject a composition comprising a therapeutically effective amount of Bowman-Birk Inhibitor wherein improved skeletal muscle function comprises increased muscle strength or increased muscle mass.

6. The method of claim 5 wherein the composition is administered orally.

7. The method of claim 6 wherein the composition is administered as a dietary supplement.

8. The method of claim 5 wherein the Bowman-Birk Inhibitor is in a concentrated form.

9. A method for treating skeletal muscle degeneration in a subject comprising administering to the subject a composition comprising a therapeutically effective amount of Bowman-Birk Inhibitor.

10. The method of claim 9 wherein the composition is administered orally.

11. The method of claim 10 wherein the Bowman-Birk Inhibitor is in a concentrated form.

12. The method of claim 9 wherein the composition comprises Bowman-Birk Inhibitor Concentrate.

13. A method for slowing progression of a degenerative skeletal muscle disorder or disease in a subject in need thereof comprising administering to the subject a composition comprising a therapeutically effective amount of Bowman-Birk Inhibitor.

14. The method of claim 13 wherein the composition is administered orally.

15. The method of claim 14 wherein the composition is administered as a dietary supplement.

16. The method of claim 13 wherein the Bowman-Birk Inhibitor is in a concentrated form.

17. The method of claim 13 wherein the degenerative skeletal muscle disorder or disease is muscular dystrophy, amyotrophic lateral sclerosis, spinal muscle atrophy or spinal cord injury.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 14, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: PTC THERAPEUTICS, INC.
Reel/Frame 053209/0872 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCLUSION OF 6420591,6583309,6503713, 5843995,7029846,7056656, 6468969,6486305,6630294, 6989256,6627398,8247167, 9017935 PREVIOUSLY RECORDED ON REEL 042418 FRAME 0774. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Aug 24, 2017
From: PTC THERAPEUTICS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 043672/0096 →
SECURITY INTEREST Recorded May 8, 2017
From: PTC THERAPEUTICS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 042418/0774 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2006
From: SWEENEY, H. LEE; MORRIS, CARL A.; KENNEDY, ANN R.
To: TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE
Reel/Frame 018610/0943 →